A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Location: Montreal, Dallas TX
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18+
Code: NCT07570979
Phase1, Recruiting
Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
for
Metastatic Castration-resistant Prostate Cancer
Location: Grand Rapids MI
Sponsor: BAMF Health
Sex: Male
Age: 18+
Code: NCT05558956
Early_phase1, Recruiting
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
for
Castration-Resistant Prostate Carcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center
Sex: Male
Age: 0+
Code: NCT05398302
Phase1, Recruiting
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
for
Castration-Resistant Prostate Carcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center
Sex: Male
Age: 0+
Code: NCT06288113
Phase2, Recruiting
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
for
Prostate Carcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center
Sex: Male
Age: 18+
Code: NCT06216249
Phase2, Recruiting
Interested in new metastatic castration-resistant prostate cancer trials?
Get alerts for new trials in your area by subscribing now
A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
for
Prostatic Neoplasms, Castration-Resistant
Location: East Hanover NJ
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT07677254
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors